Ken Griffin Beam Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 92,900 shares of BEAM stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,900
Previous 81,900
13.43%
Holding current value
$2.28 Million
Previous $1.92 Million
18.67%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$201 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$192 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$187 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$160 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$118 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.72B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...